PH-80 is under clinical development by Pherin Pharmaceuticals and currently in Phase II for Premenstrual Dysphoric Disorder (PMDD). According to GlobalData, Phase II drugs for Premenstrual Dysphoric Disorder (PMDD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PH-80 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PH-80 overview
PH-80 is under development for the treatment of premenstrual dysphoric disorder, migraine headaches and menopausal hot flashes. The therapeutic candidate is a neuroactive steroid and is administered intranasally as spray. PH-80PMD is a pherine compound that regulates functions of limbic amygdala and hypothalamus.
Pherin Pharmaceuticals overview
Pherin Pharmaceuticals (Pherin Pharma) is a clinical stage drug development company. It develops pherine based pharmaceutical products for the treatment of neuropsychiatric and neuroendocrine conditions. The company’s pipeline product comprise of Aloradine IN for acute treatment of social anxiety disorder; PH10, a nasal spray for acute treatment of depression; Salubrin HF NS, for acute management of menopausal hot flashes and other symptoms of menopause; PH10 nasal spray for mood depression ; and PH15 nasal spray for cognitive improvement. Pherin Pharma also conducts clinical trials in collaboration with other pharma companies to develop novel therapies. The company’s research and development facility develops molecule, which modulate hypothalamus and limbic areas of the brain. Pherin Pharma is headquartered in Los Altos, California, the US.
For a complete picture of PH-80’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
